Navigation Links
GenVec Presents Research on New Ad35 Adenovector at ARVO

d 85. New therapies to treat AMD have demonstrated benefit but these therapies must be injected every four to six weeks. GenVec believes its gene transfer approach may provide an effective and more convenient treatment for AMD.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of the Company's product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. GenVec's lead product, TNFerade(TM) is currently in a pivotal Phase II/III study (PACT) in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and melanoma; and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease (FMD), respiratory syncytial virus (RSV), and seasonal and pandemic flu. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization,
'"/>




Page: 1 2 3

Related medicine technology :

1. GenVec Announces Update of Safety and Efficacy Data from Pivotal Phase II/III PACT Study of TNFerade at ASCO
2. GenVec Announces New Research at AACR on Selectivity and Mechanism of Action of TNF-Based Anti-Cancer Therapy
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: GenVec Presents Research New Adenovector ARVO
(Date:5/9/2008)...iland, May 9 /PRNewswire-USNewswire/ -- An emergen...Protection of Animals (WSPA),is on stand-by in Tha...yanmar to assess and then relieve the suffering of...on for food and their livelihoods., WSPA is rec...,Organization of the United Nations (FAO) while pr...
(Date:5/9/2008)...ay 9 /- Ardea Biosciences, ...scovery and development of,small- molecule therape...atory diseases, including gout, today announced th...sident, Finance and Operations and Chief,Financial...om our board of,directors shortly thereafter. The ...
(Date:5/8/2008)... /- Globus Medical, Inc., the largest... world and a recognized,leader in motion preservat...enrollment in its SECURE(R)-C Cervical Artificial ... to mimic the normal motion of the spine in,order ...native to fusion in,the treatment of symptomatic c...
(Date:5/8/2008)...ll., May 8 /- Siemens Healt...dings (LabCorp(R)) today announced,that they have ...e,possibilities to co-develop new clinical diagnos...etabolic syndrome, oncology and diabetes. Under th...eloping new tests that,could make the biggest impa...
Breaking Medicine Technology:Animals That Cyclone Survivors Depend on Need Help Now 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4Canola Oil Can Help Americans Meet Dietary Fat Recommendations 2898 1Canola Oil Can Help Americans Meet Dietary Fat Recommendations 2898 2Brown researchers make major signal transduction discovery 2897 1Brown researchers make major signal transduction discovery 2897 2Diet com Enters Strategic Collaboration To Support Microsoft HealthVault 2894 1Diet com Enters Strategic Collaboration To Support Microsoft HealthVault 2894 2Genta to Present at Bio Investor Forum 2007 Conference 2889 1Genta to Present at Bio Investor Forum 2007 Conference 2889 2Genta to Present at Bio Investor Forum 2007 Conference 2889 3
...nt duloxetine, at,a once-daily dose of 60 mg, sign...symptoms associated with depression in a new,eigh...ents with at,least moderate pain and major depress...European Congress of Psychiatry (AEP),in Madrid, S...ommonly referred to as,serotonin and norepinephrin...
...rstCall/ --,Alfacell Corporation,s ONCONASE (ranpi...oad in antibody conjugates for cancer therapy,acc...erapeutic,Antibodies. , In a chapter of the text t...marizes preclinical research indicating that the,s...umber of tumor,models, including non-Hodgkin,s lym...
Other Medicine Technology:In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression 2In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression 3In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression 4In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression 5In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression 6Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4
(Date:5/12/2008)...-- NutraCea (OTC Bulletin Board:,NTRZ), a world le...rch and,technology, today announced financial resu...nsolidated net revenues rose 155% to $5.1 million ...dated net revenues of $2.0,million for the first q...arily due to a $860,000 increase in sales of produ...
(Date:5/12/2008)...niversity of Michigan Comprehensive Cancer Center ... patients are more likely to survive cancers of th...y, they found that cancers linked to HPV, or human...t chemotherapy and radiation treatments, while tum...actor receptor are the least responsive and most d...
(Date:5/12/2008)...e-FirstCall/ -- China Yingxia,International, Inc. ...e,Company"), a leading provider in the nutraceutic...e and distribution of organic nutritional food,pro...the People,s Republic,of China ("PRC"), announced ...ay 16, 2008, at 10:00 a.m. EDT, to discuss the Com...
(Date:5/12/2008)..., Montreal, May 12, 2008 A team of researchers ...enafil protects the heart in mice with Duchenne mu...ine Des Rosiers from the Universit de Montral and ...h Dr. Basil Petrof of the Research Institute of th...hristian Deschepper of the Institut de recherches ...
Breaking Medicine News(10 mins):Health News:NutraCea Announces First Quarter 2008 Financial Results 2Health News:NutraCea Announces First Quarter 2008 Financial Results 3Health News:NutraCea Announces First Quarter 2008 Financial Results 4Health News:NutraCea Announces First Quarter 2008 Financial Results 5Health News:NutraCea Announces First Quarter 2008 Financial Results 6Health News:HPV linked to better survival in tonsil, tongue cancer, U-M study finds 2Health News:HPV linked to better survival in tonsil, tongue cancer, U-M study finds 3Health News:China Yingxia International, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:New approach to protect the hearts of patients with muscular dystrophy 2Health News:New approach to protect the hearts of patients with muscular dystrophy 3
...educe the bio-terrorism threat of the Venezuelan e...rs at the University of Texas Medical Branch at Ga... step in the development of effective drug therapi...tis (VEE) virus, which is a potential bio-terroris...
...a safe way to monitor the fate of transplanted pan...issue of the journal Diabetes. // Researchers from...sachusetts General Hospital (MGH) said that they w...g the guidelines laid down for human transplants. ...
...ported from Rajasthan, officials say. According to...als are treating// 20 patients with symptoms of de...the maximum number of cases have been reported fro...i Madhopur districts. With dengue spreading its ...
...int task force of the American College of Chest Ph.../ and Environmental Medicine (ACOEM), and the Nati...onsistent approach to the screening and management...l motor vehicle (CMV) operators. Published as a su...
Other Medicine News:Health News:A New drug Developed To Fight The Bio-Terrorism Threat Of VEE Virus 2Health News:MRI Can Monitor Transplanted Islets 2Health News:Updated Sleep Apnea Screening Recommended for Commercial Drivers 2Health News:Updated Sleep Apnea Screening Recommended for Commercial Drivers 3Health News:Updated Sleep Apnea Screening Recommended for Commercial Drivers 4
Bird and Cronin, Inc. is a leading manufacturer of Patient Footwear, Orthopedic Softgoods, and Specialty Patient Care Products. Our products are of the highest quality and available in the USA and In
Bird and Cronin, Inc. is a leading manufacturer of Patient Footwear, Orthopedic Softgoods, and Specialty Patient Care Products. Our products are of the highest quality and available in the USA and In
...s specifically designed to treat Achilles tendonit... aircells located under the foot arch and in back ...sion with every step to help reduce swelling and e...ight neoprene fabric and is simple to apply just ...
... choice to treat arthritic pain, carpal tunnel syn... cast removal. The durable canvas glove with adju... and compression to the wrist to help relieve swel...t prevents painful wrist flexion, and holds the wr...
Medicine Products: